Eckert & Ziegler SE (LON:0NZY)
66.05
0.00 (0.00%)
At close: Jul 2, 2025
Eckert & Ziegler SE Revenue
Eckert & Ziegler SE had revenue of 68.19M EUR in the quarter ending March 31, 2025, with 0.85% growth. This brings the company's revenue in the last twelve months to 296.43M, up 15.89% year-over-year. In the year 2024, Eckert & Ziegler SE had annual revenue of 295.85M with 20.22% growth.
Revenue (ttm)
296.43M EUR
Revenue Growth
+15.89%
P/S Ratio
4.84
Revenue / Employee
273.20K EUR
Employees
1,085
Market Cap
1.20B GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 295.85M | 49.76M | 20.22% |
Dec 31, 2023 | 246.09M | 23.86M | 10.74% |
Dec 31, 2022 | 222.23M | 41.79M | 23.16% |
Dec 31, 2021 | 180.44M | 4.30M | 2.44% |
Dec 31, 2020 | 176.14M | -2.35M | -1.32% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |